Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits

Carolina G. Vital,Raul C. Maranhão,Fatima R. Freitas,Brigitte M. Van Eyll,Silvia R. Graziani

Journal of Bone Oncology（2022）

Cited 2|Views6

No score

Abstract

•LDE-PTX at 175 mg/m2/3wk dose was devoid of toxicity at > 3rd line treatment.•Among 18 LDE-PTX treated patients, 9 had PFS > 6 months and 2 had PFS > 1 yr.•LDE-PTX diminished bone pain and improved quality of life in all treated patients.

Translated text

Key words

Bone metastases treatment,Artificial nanoparticles,LDL receptor,Pain relief,Drug targeting

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined